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Migraine is a frequent and very disabling disease, especially at pediatric age. Despite
this, there are few controlled data on the prophylactic treatment of primary headaches in
this category of age. Given that the recently introduced calcitonin gene-related peptide
(CGRP) inhibitors (CGRP-r) are still limited to adulthood, there is no drug with exclusive
indication for migraine treatment in pediatric age. This raises several limitations in terms
of adherence and effectiveness of the therapy. Moreover, the scenario is complicated
by placebo response, which is larger in children and adolescents than in adults and
often leads to an improvement in the attack frequency even in absence of any active
pharmacological treatment. Our aim was to investigate the real evidence concerning
the prophylactic therapy of pediatric migraine by reviewing the clinical studies published
between 2010 and 2019.
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INTRODUCTION
According to epidemiological studies, the prevalence of headache in children varies from 5.9 to
82% (1). Migraine, the most common type of primary headache in children, is highly disabling
even in childhood and adolescence. The average prevalence of pediatric migraine varies according
to age, going from 3% in younger children to∼20% in adolescents (2). A noticeable social problem
is represented by chronic migraine (more than 15 days with headache a month) that afflicts from
0.6 to 1.8% of children and adolescents (3).
The main reference for the diagnosis of primary headaches are the criteria of the International
Headache Society (IHS) (4). These criteria have shown limitations when applied in the pediatric
age (1, 5), although the last version (ICHD 3) considers some peculiarities of migraine in pediatric
age, such as the shorted duration of pain and the unilateral/bilateral location of pain (1, 5).
Regarding therapies of pediatric migraine, there is a significant lack of clinical studies on acute
and prophylactic therapy. This is partly due to differences between countries, where therapeutic
approaches are based on cultural and political factors. Few clinical trials are available in pediatric
patients and they often show conflicting findings. The paucity of data on the effectiveness of
treatments in young migraineurs is also due to the power of placebo effect, in terms of reduction of
both frequency and intensity of migraine attacks (6). Though representing a precious resource, the
placebo effect can paradoxically represent an obstacle in controlled trials comparing the efficacy of
pharmacological and non-pharmacological treatments with placebo.
Papetti et al. A Meta-Analysis of Recent Evidences
Migraine prophylaxis aims at reducing the impact of migraine
by improving the frequency and intensity of attacks. In children
and adolescents, it should be considered when the frequency
of attacks is higher than 4 attacks per month or the response
to the symptomatic treatment is not satisfactory. In a previous
retrospective review, Papetti et al. (7) emphasized the lack of
definitive data on the possible drugs to be used.
Here, our aim is to investigate the actual evidence concerning
prophylactic therapy of pediatric migraine by reviewing clinical
studies published between 2010 and 2019.
METHODS
Literature Search Strategy
We considered studies published from January 2010 to January
2019. Medline and Cochrane library were used for the research.
Search words were: “migraine and treatment or therapy,”
“migraine and prophylaxis,” and “migraine and guidelines.” The
filters included clinical trials (CT), randomized control trials
(RCTs), open label studies (OL), retrospective studies (RS), meta-
analysis, multicenter studies, reviews and articles that were either
published in the last 10 years. Our search was focused on the
age group ranging from 0 to 18 years, although any article that
included adult population but contained patients under the age
of 18 years was also considered. Two authors (F.U. and L.P.)
independently checked the studies identified by the literature
search. All potentially relevant studies were reviewed by the
two authors.
Search Results
Using the above described strategy, 64 articles concerning
preventive treatment of migraine in children were included
in our study. Among them, there were 40 systematic reviews
or meta-analysis of the literature concerning the prophylactic
treatment of pediatric migraine, 21 clinical trials (CTs), and 3
retrospective studies (RSs). As for the CTs, 15 were randomized
control trials (RCTs) and one was an open label study (OL)
(Figure 1). All the included studies were published from 2010 to
the present. Results of current evidence are resumed in Table 1.
PHARMACOLOGICAL TREATMENT
Calcium Channel Blockers
Flunarizine is a calcium channel blocker with properties on the
cerebrovascular circulation. How flunarizine acts in preventing
migraine is not yet established but it probably has both vascular
and neuronal effects (8).
In an RS (2012), Basheer Peer et al. demonstrated that
flunarizine (2.5–10 mg/day) shows good efficacy in children
and adolescents (median age 13 years), leading to at least a
50% reduction in attack frequency in 57% of patients (41/72).
Interestingly, the response rate was particularly high in patients
with hemiplegic migraine (85%). The study also showed that
flunarizine was well-tolerated with a reasonable safety profile.
Side effects were observed in 21% of children and adolescents
and included depression, weight gain and sedation (9). In a
retrospective study of 475 patients, Kim et al. (10) showed
FIGURE 1 | Flow diagram of the study methodology.
that the efficacy and tolerability of flunarizine 5 mg/day were
comparable to those of topiramate. The responder rate (50%
reduction in headache days/month) was 80% (89/111 patients)
for flunarizine (5 or 10mg /day) and 81% (122/150 patients) for
topiramate (from 25 to 100 mg/day). The frequency of adverse
effects was higher in topiramate (10%) than flunarizine (6%) (10).
In 2014, Topcu et al. used the PedMIDAS (the score of disability
assessment in pediatric migraine) to evaluate the efficacy of
different prophylactic therapies in 53 patients, recruited from a
series of 88 patients suffering frommigraines with an age ranging
from 6 to 17 years. They found that topiramate (1–2 mg/Kg/day),
propranolol (20–40 mg/day), and flunarizine (5–10 mg/day)
significantly decreased PedMIDAS score. The number of days
with analgesic treatment significantly decreased in the patients
treated with topiramate and propranolol (p < 0.05), while it
remained unchanged in the flunarizine (p > 0.05) (11). More
recently, Toldo et al. (12) conducted a retrospective multicenter
study among 706 patients with primary headaches. Preventive
drugs were used in 19% of migraineurs and in 3% of patients with
tension-type headache (12). In patients with migraine, the most
used drug was flunarizine (18%), followed by antiepileptic drugs
(7%) and pizotifen (6%). Flunarizine and pizotifen were the most
effective drugs (72 and 82%, respectively) (12).
Flunarizine is licensed in Italy for patients over 18 years (7)
and widely prescribed in Europe, while it is not licensed in the UK
or the USA given the lack of published data in the development
age. Placebo-controlled clinical trials in pediatric age are needed
to confirm its effectiveness in pediatric migraine (13).
Beta-Blockers
Propranolol is a non-selective beta (b) adrenoceptor antagonist
that blocks the b1,2 receptors. Propranolol started to be used
in the prophylaxis of migraine for more than 50 years (14).
Propranolol showed efficacy and high profile of tolerability in
several clinical trials on adult migraine (4). On the contrary, there
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TABLE 1 | List of commonly used drugs for preventive treatment of pediatric migraine.
Drug pharmacological class Evidence
level
Dosage Side effects When to be preferred?
CALCIUM CHANNEL BLOCKERS
Flunarizine A 5–10 mg/day Sedation, dizziness, constipation, increased
appetite, weight gain
Drowsiness, asthenia, weight gain, depression
and extrapyramidal symptoms
Associated anxiety and
insomnia
not overweight patients
NON-SELECTIVE BETA ADRENOCEPTOR ANTAGONIST
Propranolol C 3 mg/kg/day Fatigue, reduction of mood, nightmares. Less
frequent adverse events: bradycardia,
orthostatic hypotension, impotence,
hallucinations, weight gain
History of
hypertension
No history of asthma or
allergy
No history
of bradyarrhythmia
TRICYCLIC ANTIDEPRESSANT
Amitriptyline B 1 mg/Kg/day Sedation, dizziness, constipation, increased
appetite, weight gain
Not obese patients
history of depression or
insomnia
chronic migraine
ANTIEPILEPTIC DRUGS
Sodium Valproate B 30 mg/kg/day Somnolence, nausea/vomiting,
thrombocytopenia,
tremor, alopecia, increased appetite, emotional
lability
History of psychosis
Male patients
Topiramate A 2–3 mg/Kg/day Paresthesia, somnolence, dizziness, anorexia,
metabolic acidosis, cognitive/memory
dysfunction
Overweight
No history of cognitive
impairment
SEROTONIN MODULATORS
Pizotifen C 1.5 mg/day Increased appetite, weight gain,
drowsiness, sleepiness, dizziness, dry mouth,
tiredness, constipation
No obese patients
history of depression or
insomnia
Cyproheptadine C 0.2–0.4
mg/kg/day
Drowsiness, fatigue, increased appetite, weight
gain, dizziness
No history of asthma
NUTRACEUTICS
Hydroxytryptophan C 100mg Kg/day Nausea, bloating
Flatulence, loose stools or diarrhea
Mild intensity of the attack
Low frequency
Refusal of pharmacological
drugs
Very young children
(<6 year)
Magnesium C 400–600
mg/day
Nausea, abdominal pain
Butterbur(petasites hybridus) C 100–150mg Burping or belching
Itchy eyes, diarrhea, difficulty breathing,
drowsiness, liver toxicity
Riboflavin C 400 mg/day Diarrhea, increased urine
Coenzyme Q10 C 150–300
mg/day
Nausea and/or vomiting
upset stomach, diarrhea
heartburn, loss of appetite, abdominal pain or
discomfort
Tenacetum parthenium –Feverfew (MIG99) C 6.25mg
18.75mg TID/day
Abdominal pain, mouth ulcers, bloating,
diarrhea, nausea
RS, Retrospective Study; RMS, Retrospective Multicenter Study; RCT, Randomized Controlled Trial; TPM, topiramate; PZT, pizotifen; VPA, valproic acid; AMI, amitriptyline; PGB,
pregabalin; PPL, propranolol; FNZ, flunarizine; CNZ, cinnarizine.
are only a few studies supporting the efficacy of propranolol in
pediatric age (15–17).
In 2010, Bidabadi et al. compared the efficacy and safety of
propranolol (started at a dosage of 3 mg/kg/day) and valproate
(30 mg/Kg/day) for migraine prophylaxis in childhood. In
this study, 60 patients were enrolled (30 in the group A that
received propranolol 3 mg/kg/day and 30 in the group B
treated by sodium valproate 30 mg/kg/day). The mean age of
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the patients was 9.85 ± 2.63 years. Headache frequency was
significantly reduced by more than 50% in 83% of patients
treated with propranolol and in 63% of patients treated with
sodium valproate without significant differences between the
drugs. Furthermore, no significant difference in side effects
between the two groups was found (18). Eidlitz-Markus et al. (19)
compared the efficacy of a low dose of propranolol (the initial
dose was 0.47± 0.17 mg/kg/day) with a low dose of amitriptyline
(mean initial dose, 0.26 ± 0.1 mg/kg/day) in children and
adolescent suffering from severe migraine. Although the study
was not blinded and placebo controlled, it included a large
number of patients (118 with a mean age of 12.54 ± 3.14
years). Both propranolol and amitriptyline, when combined with
non-pharmacologic treatments, showed efficacy in reducing the
frequency of migraine attacks in children (reduction of attack
frequency >50% per month in 80% of patients). Propranolol
group showed less frequent side effects (19). In 2012, Fallah
et al. compared efficacy and safety of propranolol (1 mg/kg/day)
and topiramate (3 mg/kg/day) in a parallel single-blinded
randomized clinical trial. Authors enrolled 100 patients that were
divided in two groups (50 patients treated with propranolol
and 50 patients treated with topiramate). After 3 months of
treatment, 62% of patients treated with propranolol and 82%
of patients treated with topiramate showed more than a 50%
reduction in monthly headache frequency (p < 0.05). No serious
adverse events were seen in both groups and, in particular, the
main side effects after treatment with propranolol were mild
hypotension and drowsiness (20). In a RCT (2013), Bakhshandeh
Bali et al. compared effectiveness, safety and tolerability of
propranolol (10 to 20 mg/day divided in two doses; group b)
and pregabalin (50 to 75 mg/day; group a). After 4 and 8 weeks
of pregabalin administration, headache frequency was reduced
by 81.8 and 85.45%, respectively. Using the same treatment
intervals, propranolol reduced monthly headache frequency by
64.54 and 68.25%, respectively. The difference between drugs was
statistically significant (p= 0.04) (21).
Recent data showed that beta-blockers are rarely used in Italy,
probably because their tolerability profile is not excellent and they
are licensed over 18 years (4).
Tricyclic Antidepressant
Amitriptyline is one of the most used drugs for preventive
treatment of pediatric migraine (22). It is also recommended in
cases of tension-type headache associated with anxiety, insomnia
and depression (22). Efficacy of amitriptyline prophylaxis is
achieved with much lower doses than those required for anti-
depressive therapy (10–20 mg/day up to 25–75 mg/day) (7).
It is advisable to use increasing doses before reaching the
maintenance dose in order to reduce the side effects and
improve tolerability. Contraindications are cardiac, hepatic,
renal, prostatic and thyroid diseases; glaucoma, hypotension,
epilepsy, use of anti-MAO. Amitriptyline also should be used
with caution for its anticholinergic effects. The most frequent
adverse events are dry mouth, constipation, sedation, and
increase in appetite, increased weight, occasionally orthostatic
hypotension and cardiotoxicity (22).
As reported above, it was shown that low-dose propranolol
and low-dose amitriptyline, if combined with non-
pharmacological measures, were both effective in reducing
migraine attacks frequency (19). Between July 2012 and
November 2014, Hershey et al. conducted a double-blinded,
placebo-controlled study with the aim to determine the most
effective prophylactic treatment in children and adolescents
(CHAMP study). Authors compared the efficacy of amitriptyline,
topiramate, and placebo in 361 subjects (from 8 to 17 years
of age). In a period of 6 months, 52% of patients receiving
amitriptyline (dose 1 mg/kg per day), 55% of patients receiving
topiramate (dose 2 mg/kg per day), and 61% of patients receiving
placebo had a reduction in headache days of at least 50%, without
any significant difference between groups. Furthermore, the
patients treated with amitriptyline or topiramate presented
higher rates of adverse events compared to placebo control group
(23). In conclusion, considering the negative outcome of this
study in terms of efficacy and the increased risk of undesirable
effects from amitriptyline or topiramate in this sensitive category
of patients, the benefit / risk ratio of these drugs is considered
unfavorable. In an Iranian parallel, single-blinded randomized
clinical trial, the efficacy of amitriptyline (1 mg/kg/day) was
compared to melatonin (0.3 mg/kg/day) in a population of
migraineurs ranging from 5 to 15 years. A reduction of more
than 50% in monthly headache frequency was seen in 82.5 and
62%.5 of patients treated with amitriptyline and melatonin,
respectively. Amitriptyline was significantly more effective (P =
0.04) (24). Amitriptyline showed a good efficacy for treatment
of chronic headaches in association with cognitive behavioral
therapy (25–28).
Antiepileptic Drugs
Sodium Valproate (500–1,500 mg/day) and topiramate (50–100
mg/day) were evaluated for prophylactic therapy of pediatric
migraine in some controlled studies (7).
In the last 8 years, one RCT compared the efficacy of valproate
and propranolol for the preventive treatment of migraine in the
pediatric age. Sixty children (aged 5–15 years) with migraine
without aura were included. Patients received propranolol (3
mg/kg/day) or sodium valproate (30 mg/kg/day) for at least
6 months. The main endpoint (reduction of more than 50%
in monthly headache frequency) was observed in 83% of the
propranolol group and in 63% of sodium valproate groupwithout
statistical significance. The global reduction of baseline headache
frequency was better in the group of propranolol (p < 0.05) (18).
Topiramate is a first-line strategy for the treatment ofmigraine
in adults. In 2014, the U.S. Food and Drug Administration (FDA)
approved topiramate for migraine treatment in the pediatric
patients aged 12 to 17 years (29). In adults, topiramate proved
efficacious in the preventive treatment of migraine with and
without aura in episodic and chronic form, and excessive use
of symptomatic drugs (24, 30). In a parallel single-blinded
randomized clinical pediatric trial, the efficacy and safety of
topiramate (3 mg/Kg/day) and propranolol (1 mg/Kg/day) were
compared, and the results showed that topiramate was more
effective in reducing the monthly frequency, severity, duration
and disability of the headache. Topiramate was superior to
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propranolol in reducing the frequency of the attacks by at
least 50% (respectively 82 vs. 62% of patients) (31). In another
study by the same authors, recruiting a population of 100
pediatric patients (mean age of 10.46 ± 2.11 years) treated
with topiramate (3 mg/kg/day), the frequency and duration of
headache attacks reduced from 15.34 ± 7.28 to 6.07 ± 3.16
attacks and from 2.28 ± 1.55 to 0.94 ± 0.35 h, respectively.
The pediatric migraine disability assessment score was reduced
from 32.4 ± 9.3 to 15.5 ± 6. Side-effects were seen in 21%
of the patients, including hyperthermia, anorexia and weight
loss, and drowsiness (32). Authors concluded that topiramate
could be considered a safe and effective drug for migraine
therapy in pediatric patients (32). As reported above, Kim et al.
showed that the response rate, retention rate and the rate of side
effects were not significantly different between flunarizine and
topiramate (10). In a randomized, double-blind clinical study
of 44 migraineurs (aged 4–15 years), Ashrafi et al. compared
the efficacy and safety of cinnarizine and topiramate in the
prevention of pediatric migraine. The primary endpoint was the
monthly frequency of migraine. Measures of secondary efficacy
were the intensity ofmonthlymigraine and a response rate higher
than 50%. During the double-blind phase of the study (week 8),
both patients treated with cinnarizine and topiramate showed a
statistically significant 50% responder rate (cinnarizine: 55%, p
= 0.004; topiramate: 50%, p = 0.001). Also monthly migraine
intensity reduced in both groups (p < 0.001) (33). After 12
weeks of treatment, a significant reduction of monthly migraine
frequency was observed for both cinnarizine and topiramate (p
< 0.05) with no significant differences between groups (33).
The CHAMP study failed in showing any superiority of
treatment with amitriptyline or topiramate, as compared to
placebo (23).
Verapamil, levetiracetam and zonisamide have also been
studied for treatment of migraine, but there is a lack of evidence
supporting their use in the pediatric population (34).
Serotonin Modulators
Pizotifen was studied in a placebo controlled trial conducted
on 37 subjects (6–15 years), at a dosage of 1.5 mg/day, with a
significant reduction in attack frequency and mild side effects
(35). In a subsequent controlled study, the dose of 1–1.5mg,
administered for 6 months in 47 migraine subjects (7–14 years),
was not more effective than placebo. Side effects consisted of
sedation, increase in appetite and weight (36). In the last decade,
no trials have been conducted on pizotifen from which definitive
efficacy data can be drawn.
Cyproheptadine was first evaluated in an open study at a
dosage of 0.2–0.4 mg/kg/day for 3–6 months, achieving a good
improvement (68%) and a remission (21%) of the headache (37).
This substance, usually used in younger patients, can have the
same side effects as pizotifen, that is drowsiness, weight gain and
tenderness. Contraindications consist of asthma, glaucoma and
peptic ulcer.
Despite the lack of definitive data, Pizotifen is the only licensed
drug in Italy for prophylaxis in migraineurs children (7, 38).
A recent survey on treatments for primary headaches, in
13 specialized juvenile Italian headache centers, reported that
pizotifen (1 mg/kg/day) was one of the most efficacious (82%
perceived by patients) and tolerated treatments for migraineurs
children (12).
NON-PHARMACOLOGICAL APPROACH
Nutraceutics and Herbals
The term Nutraceutical refers to all those compounds that
derive from “nutrition” and “pharmaceutical.” It refers to the
study of active ingredients of food origin that are supposed
to have a beneficial function on human health. More active
ingredients can be combined with each other to enhance their
effects. The term “herbal” refers to all those compounds, such as
plants or derivatives of medicinal plants. In general, nutraceutics
are chosen to have fewer side effects and a more “natural”
approach to the treatment of the disease. These products are
generally marked in the absence of validative studies (efficacy and
safety) (39).
Data on the use of nutraceuticals and herbals are available for
the following molecules: magnesium, riboflavin, coenzyme Q10,
butterbur, feverfew and hydroxytryptophan (40).
The rationale of the use of nutraceutics in the treatment of
migraine is based on the involvement of these substances in
anti-inflammatory or antioxidant molecular pathways or in the
mitochondrial energy activity (39).
Despite the widespread use in clinical practice, there are
few RCTs available for these substances. Thus, the level
of evidence remains low (level b or c), as well as the
recommendation (class III).
The few RCTs on magnesium, riboflavin, feverfew, and
hydroxytryptophan are prior to 2010 and have not shown
conclusive results (41–43).
A more recent RCT investigated the effect of coenzyme Q10
(100 mg/day) in the prophylaxis of pediatric migraine (44). A
significant reduction in migraine frequency (p < 0.001), severity
(p < 0.05), and duration (p < 0.05) was equally found in the
placebo and CoQ10 groups (44).
Ginkolide B, in combination with other nutraceutics, was
studied in pediatric open label studies. It is a platelet-activating
factor (PAF) receptor antagonist, and would modulate pro-
inflammatory mechanisms (42). One open-label trial verified the
efficacy of a complex of ginkgolide B, coenzyme Q10, riboflavin
and magnesium (doses not specified) in pediatric patients with
migraine. After 3 months of treatment, the number of attacks
in a month was significantly lower (45). Another open label
study compared the efficacy of a combination of ginkgolide B (80
mg/day), coenzyme Q10 (20 mg/day), riboflavin (1.6 mg/day),
and magnesium (300 mg/day) with a complex of L-tryptophan
(250 mg/day), 5-hydroxytryptophan (50 mg/day), vitamin PP (9
mg/day), and vitamin B6 (1 mg/day) for a treatment period of
6 months. Both combinations were associated with a significant
reduction of frequency of headache attacks with a major effect for
the complex including ginkgolide B (39, 40).
Onabotulinumtoxin A
The use of botulinum toxin proved promising in adult patients
with migraine, and in particular, its efficacy has been recognized
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in adults with chronic migraine. However, there are few
retrospective data regarding the pediatric experience. This
treatment is particularly useful in patients that present side effects
of oral drugs or in drug resistant migraine (46). In a retrospective
case series study, Ahmed et al evaluated tolerability and efficacy
of botulinum toxin type A in the treatment of pediatric chronic
headache (47). The study included 10 patients with age ranging
from 11 to 17 years who received a standard 100-unit dose of
onabotulinumtoxin A. The patients had attempted an average of
8.0 ± 2.40 SD therapies prior to botulinum toxin. A decrease
in headache intensity was observed in 40% of patients and 20%
noted a decrease in headache frequency with global improvement
in quality of life (47). In 2012, Kabbouche et al. reviewed the
data of pediatric patients who had received Onabotulinumtoxin
A (average dose of 188.5 units±32 with a minimum dose of 75
units and maximum of 200) for chronic migraine in a pediatric
headache center from 2004 to 2010. A significant reduction in
the frequency of the headache attacks was observed (from 27.4
headache per month±5.2 to 21.3 ± 10.3; p < 0.05), while there
was no significant change in the severity of pain (48).
Complementary Therapies
Non-pharmacological treatment for pediatric migraine includes
cognitive behavioral therapy, acupuncture, and biofeedback.
As stated above, cognitive behavioral therapy (CBT) proved
effective in treating chronic forms of migraine, although the best
results were observed when this therapy was combined with
pharmacological therapy, in particular amitriptyline (25–28).
A randomized study conducted on 135 patients (mean age
14.4 ± 2) with chronic migraine evaluated the efficacy at 20
weeks of the combined treatment with CBT plus amitriptyline
vs. headache education plus amitriptyline. The authors found
that 47% of patients in the CBT plus amitriptyline group had
less than four headache days per month compared to 20% in
the headache education plus amitriptyline group (p < 0.005).
At 12 months post treatment, 72% of patients in the CBT plus
amitriptyline group had less than four headache days per month
compared to 52% in the headache education plus amitriptyline
group (p < 0.05) (27).
In a recent RCT, two different training programs [multimodal
cognitive-behavioral training (CBT) and applied relaxation (AR)]
were compared with an educational intervention (EDU). Sixty-
five children and adolescents with at least 2 attacks of headache
per month were assigned to one of the three group. The main
outcome endpoints included changes in headache frequency,
intensity and duration, responder rate (50% reduction of
headache frequency), and number of the attacks needed to treat
(NNT). All three groups presented a significant reduction in
headache frequency and duration, while no significant differences
were observed in the intensity of pain. The group of CBT
showed the highest responder rates (50% reduction of headache
frequency) after 4 weeks of treatment (63 vs. 32% of AR and 19%
of EDU). However, at follow-up after six months, no significant
differences were found in the NNTs (CBT: 63%, AR: 56%,
EDU: 55%). At follow-up assessment, the effects of the headache
frequency remained stable in all groups (49).
There is only limited data on the use of acupuncture for the
treatment of pediatric migraine. While efficacy of acupuncture in
reducing the frequency of the attacks of migraine was shown in
earlier studies (50, 51), no further result has been published in the
last 10 years.
Although there are no studies in the last decade on the efficacy
of biofeedback for the treatment of pediatric migraine, a recent
meta-analysis resumes the main findings on this topic (52). It
concludes that biofeedback showed efficacy in reducing attack
frequency (p < 0.001) and duration (p < 0.001), and intensity
of pain (p < 0.001). However, biofeedback demonstrated no
adjuvant effect when combined with other behavioral and no
more benefits than pharmacological treatment (52). It is worth
to be underlined that data on biofeedback comes only from
retrospective studies or pilot studies (53–55).
Overall, non-pharmacological treatment for migraine can be a
valid alternative for selected patients.
The choice of a non-pharmacological therapy should be
reserved for patients who have failed drug therapies or, as a first
line treatment, in patients who cannot tolerate the side effects of
drugs. However, most published studies on non-pharmacological
treatments have been carried out in adults, while definite
results in children and adolescents are still lacking. Therefore,
further confirmation with rigorous randomized controlled trials
is mandatory for the majority of these approaches (56).
FURTHER CONSIDERATIONS AND
FUTURE PROSPECTIVES
Themain novelty of the last decade in the prophylaxis of pediatric
migraine comes from the results of the CHAMP study. This study
showed that pharmacological treatments, such as amitriptyline
and topiramate, do not differ from placebo. Three main issues
are raised by this study:
- First, placebo effect proves very powerful in pediatric age
(about 60% of patients), thus it should be considered as a
fundamental therapeutic resource. Placebo response rate is
known to be high in pediatric migraine studies (25). The high
therapeutic efficacy of placebo should not be considered only
as a threat to the success of clinical studies, but it represents a
therapeutic possibility in the treatment of pediatric migraine.
Research should be addressed to further investigate the
exact mechanisms connected with high placebo response
rate in children with migraine. A higher knowledge in this
field could allow us to use placebo as a non-harmful and
effective treatment.
- The CHAMP study get us to wonder whether the use of
pharmacological treatment is still allowed. Although the
CHAMP results must be taken into account, we cannot forget
the results of other RCTs reviewed in the present study and
supporting the efficacy of some pharmacological treatments.
Moreover, CHAMP trial did not consider some dynamics that
may influence the course of migraine independently of drug
therapy, such as psychological factors mostly linked to school
attendance. It is known that untreated young migraineurs
have a lower frequency of attacks in summer months, while
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they suffer more after the start of the school (57, 58). This
means that whether the efficacy of placebo is measured in a
favorable (e.g., from February to August), or unfavorable (e.g.,
fromAugust to February) period can influence the response to
therapy. In conclusion, we believe that CHAMP study should
induce us to be even more rigorous in the treatment selection,
considering the evidence-based data of efficacy and safety as
being crucial for the therapeutic choice.
- Lastly, we must underline that there is no drug available in
pediatric age with exclusive indication for migraine treatment
(59). From this point of view, there is high expectation for
the use of calcitonin gene-related peptide (CGRP) inhibitors
(CGRP-r). The large trials conducted in the adult population
(60, 61) have led Food and Drug Administration (FDA)
to give the green light to commercialization of these drugs
(Erenumab; Galcanezumab; Fremanezumab) in USA. The
same drugs have been recently approved from European
Medicines Agency (Erenumab; Galcanezumab). Although
results from trials in children and adolescents are not
available yet, the Pediatric and Adolescent Headache special
interest group of the American Headache Society proposed
recommendations on the use of these agents for pediatric
headache disorders (62). The authors suggested that the
use of CGRP receptor antagonists could be considered
in postpubertal adolescent patients with frequent migraine
attacks (≥8 headache days/month), who have moderate
to severe disability associated with migraine (PedMIDAS
score ≥30) and have failed ≥2 preventive therapies. For
younger patients, who are refractory to multiple preventive
therapies, CGRP receptor antagonists may also be considered
with proper monitoring (e.g., bone health, linear growth,
weight/BMI, infections) (62).
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